You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Will New Guidelines on Antibiotic Stewardship Help in Future Pandemics?

  • Authors: News Author: Marta Zaraska; CME Author: Charles P. Vega, MD
  • CME / ABIM MOC / CE Released: 11/11/2022
  • Valid for credit through: 11/11/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.25 ABIM MOC points

    Nurses - 0.25 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)

    Pharmacists - 0.25 Knowledge-based ACPE (0.025 CEUs)

    Physician Assistant - 0.25 AAPA hour(s) of Category I credit

    IPCE - 0.25 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for primary care physicians, infectious disease specialists, nurses, nurse practitioners, pharmacists, physician assistants, and other members of the healthcare team who prescribe or manage antimicrobial drugs.

The goal of this activity is for the healthcare team to be better able to evaluate the application of antimicrobial treatment for patients with COVID-19.

Upon completion of this activity, participants will:

  • Assess rates of co-infection and secondary infection with SARS-CoV-2, the virus that causes COVID-19
  • Evaluate the application of antimicrobial treatment for patients with COVID-19
  • Outline implications for the healthcare team


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


News Author

  • Marta Zaraska

    Freelance writer, Medscape

    Disclosures

    Marta Zaraska has no relevant financial relationships.

CME Author

  • Charles P. Vega, MD

    Health Sciences Clinical Professor of Family Medicine
    University of California, Irvine School of Medicine
     

    Disclosures

    Charles P. Vega, MD, has the following relevant financial relationships:
    Consultant or advisor for: GlaxoSmithKline; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
     

Editor/Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Nurse Planner

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Contact This Provider

    For Nurses

  • Awarded 0.25 contact hour(s) of continuing nursing education for RNs and APNs; none of these credits is in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape, LLC designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number JA0007105-0000-22-372-H01-P).

    Contact This Provider

  • For Physician Assistants

    Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 11/11/2023. PAs should only claim credit commensurate with the extent of their participation.

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Will New Guidelines on Antibiotic Stewardship Help in Future Pandemics?

Authors: News Author: Marta Zaraska; CME Author: Charles P. Vega, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 11/11/2022

Valid for credit through: 11/11/2023

processing....

Note: The information on the coronavirus outbreak is continually evolving. The content within this activity serves as a historical reference to the information that was available at the time of this publication. We continue to add to the collection of activities on this subject as new information becomes available. It is the policy of Medscape Education to avoid the mention of brand names or specific manufacturers in accredited educational activities. However, manufacturer names related to the approved COVID-19 vaccines are provided in this activity in an effort to promote clarity. The use of manufacturer names should not be viewed as an endorsement by Medscape of any specific product or manufacturer.

Clinical Context

Antimicrobial stewardship has not always been top-of-mind during the COVID-19 pandemic, and the authors of the current study described the different forces affecting antimicrobial prescribing from 2020 to the present time. Early reports from China at the outset of the pandemic conveyed that up to half of all deaths related to COVID-19 were due to secondary infection; however, subsequent studies found rates of co-infection of SARS-CoV-2, the virus that causes COVID-19, with other organisms in 3.5% of hospitalized patients, and 14.3% of these patients developed secondary infections.

Of course, the high risk for hospitalization and mortality and lack of clear guidelines or treatment alternatives for the management of COVID-19 also contributed to antimicrobial overuse, but the authors of the current review noted that this phenomenon was most prevalent early in the pandemic and faded with time. The effect of COVID-19 on antimicrobial resistance patterns is largely unknown.

The current study by Khan and colleagues provides a review of research into the use of antimicrobial drugs during the COVID-19 pandemic.

Study Synopsis and Perspective

A statement by the Society for Healthcare Epidemiology of America (SHEA), published online on September 14 in Infection Control & Hospital Epidemiology,[1] offers healthcare providers guidelines on how to prevent inappropriate antibiotic use in future pandemics and avoid some of the negative scenarios that have been seen with COVID-19.

According to the US Centers of Disease Control and Prevention (CDC),[2] the COVID-19 pandemic brought an alarming increase in antimicrobial resistance in hospitals, with infections and deaths caused by resistant bacteria and fungi going up by 15%. For some pathogens, such as the Carbapenem-resistant Acinetobacter, that number is now as high as 78%.

The culprit might be the widespread antibiotic overprescription during the current pandemic. A 2022 meta-analysis[3] revealed that in high-income countries, 58% of patients with COVID-19 were given antibiotics, whereas in lower- and middle-income countries, 89% of patients were put on such drugs. Some hospitals in Europe[4] and the United States[5] reported similarly elevated numbers, sometimes approaching 100%.

"We've lost control," Natasha Pettit, PharmD, pharmacy director at University of Chicago Medicine, told Medscape Medical News. Pettit was not involved in the SHEA study.

"Even if CDC didn't come out with that data I can tell you right now, more of my time is spent trying to figure out how to manage these multi-drug-resistant infections, and we are running out of options for these patients," added Pettit.

"Dealing with uncertainty, exhaustion, critical illness in often young, otherwise healthy patients, meant doctors wanted to do something for their patients," said Tamar Barlam, MD, an infectious diseases expert at the Boston Medical Center who led the development of the SHEA white paper, in an interview with Medscape Medical News.

That something often was a prescription for antibiotics, even without a clear indication that they were actually needed. A British study[6] revealed that in times of pandemic uncertainty, physicians often reached for antibiotics "just in case" and referred to conservative prescribing as "bravery."

Studies have shown, however, that bacterial co-infections in COVID-19 are rare. A 2020 meta-analysis[7] of 24 studies concluded that only 3.5% of patients had a bacterial co-infection on presentation, and 14.3% had a secondary infection. Similar patterns had previously been observed in other viral outbreaks. Research on MERS-CoV,[8] for example, documented only 1% of patients with a bacterial co-infection on admission. During the 2009 H1N1 influenza pandemic, that number was 12% of non-intensive care unit (ICU) hospitalized patients.

Yet, according to Pettit, even when such data became available, it did not necessarily change prescribing patterns.

"Information was coming at us so quickly, I think the providers didn't have a moment to see the data, to understand what it meant for their prescribing. Having external guidance earlier on would have been hugely helpful," she told Medscape Medical News.

That is where the newly published SHEA statement comes in: It outlines recommendations on when to prescribe antibiotics during a respiratory viral pandemic, what tests to order, and when to deescalate or discontinue the treatment. These recommendations include, for instance, advice to not trust inflammatory markers as reliable indicators of bacterial or fungal infection and to not use procalcitonin routinely to aid in the decision to initiate antibiotics.

According to Barlam, one of the crucial lessons here is that if physicians see patients with symptoms that are consistent with the current pandemic, they should trust their own impressions and avoid reaching for antimicrobials "just in case."

Another important lesson is that antibiotic stewardship programs have a huge role to play during pandemics. They should monitor prescribing and also compile new information on bacterial co-infections as it gets released and make sure it reaches the physicians in a clear form.

Evidence suggests that such programs and guidelines do work to limit unnecessary antibiotic use. In one medical center in Chicago, for example, before recommendations on when to initiate and discontinue antimicrobials were released, over 74% of patients with COVID-19 received antibiotics. After guidelines were put in place, the use of such drugs fell to 42%.

Pettit believes, however, that it is important not to leave each medical center to its own devices.

"Hindsight is always twenty-twenty," she said, "but I think It would be great that if we start hearing about a pathogen that might lead to another pandemic, we should have a mechanism in place to call together an expert body to get guidance for how antimicrobial stewardship programs should get involved."

One of the authors of the SHEA statement, Susan Seo, reports an investigator-initiated Merck & Co., Inc. grant on cost-effectiveness of letermovir in patients with hematopoietic stem cell transplant. Another author, Graeme Forrest, reports a clinical study grant from Regeneron Pharmaceuticals, Inc. for inpatient monoclonals against SARS-CoV-2. All other authors report no conflicts of interest. The study was independently supported.

Study Highlights

  • Researchers searched for studies that included ≥ 50 patients with laboratory-confirmed COVID-19. All studies had to include a focus on antimicrobial use.
  • The main study outcome was the trend in antimicrobial use during the pandemic. The research team performed a subanalysis to compare this outcome in high- and middle-/low-income countries.
  • The initial search yielded 1671 articles, and 43 underwent complete analysis. 33 studies were completed in high-income countries, and 34 studies focused on hospital or other secondary-care services.
  • 35 studies were judged to be of satisfactory or good quality.
  • 2 studies that compared the use of antimicrobial drugs in the United States in early 2020 vs previous years found conflicting results. In one study, there was little change in the use of antimicrobials during the pandemic. In the other study, antimicrobial prescriptions actually declined.
  • In contrast, several studies from Europe demonstrated that antimicrobial use increased in 2020 vs previous years: 23% of antimicrobial prescriptions were judged to be inappropriate in one study.
  • In a study from Pakistan, 88% of antimicrobial prescriptions were not preceded by any testing for pathogens. Unsurprisingly, the pandemic was associated with higher rates of antimicrobial prescribing there.
  • 27 studies provided data for a meta-analysis of the overall rate of antimicrobial use during infection with SARS-CoV-2, the virus that causes COVID-19; 68% of patients with COVID-19 were prescribed antimicrobial drugs.
  • There was a profound difference in overall antimicrobial use in comparing high-income countries (58%) and middle-/low-income countries (89%).
  • The most commonly prescribed antimicrobials among patients with COVID-19 included ceftriaxone, azithromycin, and piperacillin-tazobactam. Azithromycin use was particularly common at the outset of the pandemic.

Figure. Use of Antimicrobial Agents During Infection With COVID-19

Clinical Implications

  • Early reports from China at the outset of the pandemic described that up to half of all deaths related to COVID-19 were due to secondary infection; however, subsequent studies found rates of bacterial co-infection of COVID-19 in 3.5% of hospitalized patients, and 14.3% of these patients developed secondary infections.
  • The current meta-analysis by Khan and colleagues found that 68% of patients with COVID-19 received antimicrobial drugs. This difference was particularly marked in middle-/low-income countries. The most commonly prescribed antimicrobials among patients with COVID-19 included ceftriaxone, azithromycin, and piperacillin-tazobactam.

Implications for the Healthcare Team

The healthcare team should continue good stewardship practice to prevent the inapproriate use of antimicrobial drugs during the COVID-19 pandemic.

Earn Credit